-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $275

Benzinga·08/28/2026 12:54:10
Listen to the news
Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.